Elamipretide / SS-31
Forzinity has accelerated approval for a narrow Barth-syndrome population, not general anti-aging use.
FDA-approved product context
Forzinity has accelerated approval for a narrow Barth-syndrome population, not general anti-aging use.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
FDA announced accelerated approval of Forzinity (elamipretide) injection on September 19, 2025 for Barth syndrome in patients weighing at least 30 kg. This is a defined prescription-product indication.
Proponents also describe SS-31 as a mitochondrial or healthy-aging compound. The Barth-syndrome approval does not establish benefit for healthy people, anti-aging or unrelated research-chemical preparations.
FDA based accelerated approval on knee-muscle strength considered reasonably likely to predict patient benefit. A confirmatory trial is required. Injection-site reactions and serious reactions have been reported. No dosing or administration instructions are provided.
Original source: Elamipretide / SS-31 ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.